As an adjunct to diet, CRESTOR® (rosuvastatin calcium) is indicated
to lower LDL-C, raise HDL-C, and is approved to slow the progression of
atherosclerosis in adult patients as part of a treatment strategy to lower
cholesterol to target levels.
Reduce LDL-C and raise HDL-C
CRESTOR is indicated along with diet to reduce elevated Total-C, LDL-C, ApoB,
non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary
hyperlipidemia or mixed dyslipidemia.
-
Lower LDL-C and raise HDL-C with a low 10-mg dose of CRESTOR
-
In patients with type 2 diabetes, up to 94%‡ achieved LDL-C goal of
<100 mg/dL§ with a starting dose of CRESTOR 10 mg,,
-
Safety profile in line with other leading statins,
±In 3 titration trials of patients with type
2 diabetes treated with a starting dose of CRESTOR 10 mg.
In the ANDROMEDA trial (n=240), 94% reached LDL-C goal of <96.5 mg/dL at 8
weeks. There was a mean LDL-C reduction of 51% from baseline of 131 mg/dL. The
primary end point was the percentage change from baseline in LDL-C after 16
weeks.
In the CORALL trial (n=130), 82% reached LDL-C goal of <100 mg/dL at 6
weeks. There was a mean LDL-C reduction of 46% from baseline of 164 mg/dL. The
primary end point, the percentage change from baseline in ApoB/ApoA1 ratio
after 6 weeks, was not significantly different between CRESTOR and
atorvastatin. LDL-C goal achievement was another end point.
In the URANUS trial (n=232), 65% reached LDL-C goal of <100 mg/dL at 4
weeks. There was a mean LDL-C reduction of 48% from baseline of 178 mg/dL. The
primary end point was the percentage change from baseline in LDL-C after 16
weeks.
§According to the update to the third report of the National Cholesterol
Education Program Adult Treatment Panel (NCEP ATP III), the LDL-C goal
is <160 mg/dL for lower-risk patients, <130 mg/dL for moderate-risk
patients, <130 mg/dL (optional goal of <100 mg/dL)
for moderately high-risk patients, <100 mg/dL
for high-risk patients, and an optional goal of <70 mg/dL
for very high-risk patients.
Slow the progression of atherosclerosis
As an adjunct to diet, CRESTOR is approved to slow the progression of
atherosclerosis in at-risk patients as part of a treatment strategy to lower
Total-C and LDL-C to target levels.
CRESTOR is not indicated to reduce cardiovascular morbidity and
mortality.
Atherosclerosis is a common, progressive vascular disease.,
Atherosclerotic plaques can progress significantly before they are detected.,
Is your statin of choice indicated to slow the progression of atherosclerosis?
‖Multiple generic formulations are widely available.
¶Statin combination = a fixed-dose combination of 2 agents.
CRESTOR is not indicated to reduce cardiovascular morbidity and mortality.
Fluvastatin is indicated to reduce the risk of undergoing coronary revascularization procedures in patients with CHD.
Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures.
Pravastatin is indicated to reduce the risk of myocardial infarction (MI), undergoing myocardial revascularization procedures, and the risk of cardiovascular mortality with no increase in death from noncardiovascular causes in patients without clinically evident coronary heart disease (CHD). Pravastatin is also indicated in patients with clinically evident CHD to reduce the risk of total mortality by reducing coronary death, MI, undergoing myocardial revascularization procedures, and stroke.
Atorvastatin is indicated to reduce the risk of myocardial infarction (MI), stroke, revascularization procedures, and angina in adult patients without clinically evident coronary heart disease (CHD) but with multiple risk factors for CHD. Atorvastatin is indicated in patients with type 2 diabetes, without clinically evident CHD but with multiple risk factors for CHD, to reduce the risk of MI and stroke. Atorvastatin is also indicated to reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in patients with clinically evident CHD.
Simvastatin is indicated to reduce the risk of total mortality by reducing coronary heart disease deaths, non-fatal myocardial infraction and stroke, and coronary and non-coronary revascularization procedures in patients at increased risk of coronary events.
No incremental benefit of Vytorin on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.
Lescol and Lescol XL are registered trademarks of Novartis
Pharmaceuticals Corporation.
Mevacor is a registered trademark of Merck & Co., Inc.
Pravachol is a registered trademark of Bristol-Myers Squibb
Company.
Lipitor is a registered trademark of Pfizer Inc.
Zocor is a registered trademark of Merck & Co., Inc.
Vytorin is a registered trademark of MSP Singapore Company,
LLC.
Help your at-risk patients understand atherosclerosis
There is an opportunity to raise awareness about atherosclerosis. The ongoing
dialogue you have with your at-risk patients builds greater understanding about
this prevalent health condition. By educating your patients about
atherosclerosis, we can
-
Raise awareness about the disease
-
Communicate the importance of cholesterol management
-
Call attention to the link between cholesterol and arterial plaque buildup
-
Motivate at-risk patients to take better care of their arteries
See how AstraZeneca is helping
educate at-risk patients about atherosclerosis.